This is the first real decision week of the June board. SPRO / tebipenem HBr is the next clean approval clock on Thursday, June 18. The review is supported by GSK’s resubmission and the Phase 3 PIVOT-PO package, with the core question still straightforward: can FDA clear the first oral carbapenem option for complicated UTI, including pyelonephritis?
ACHV / cytisinicline follows on Saturday, June 20, but that is no longer a clean approval binary. Achieve has already said it expects a CRL tied to manufacturing / inspection issues and is planning a Q4 2026 resubmission with Adare Pharma Solutions as commercial manufacturer.
The late-June cluster remains ARQT, LNTH, and IONS. Then VERA and CELC carry the board into July, with MNKD now entering the outer edge of the six-week window.
|
!
|
CAMX.ST / OCLAIZ — CRL · Jun 10
Camurus received a complete response letter for Oclaiz in acromegaly. The CRL relates to unresolved observations from a third-party manufacturer inspection, not clinical efficacy or safety. Oclaiz moves off the live approval board and into the CMC reset bucket.
|
|
··
|
ACHV / CYTISINICLINE — KEEP AS CRL EXPECTED
The raw file still shows a high PoA, but the company’s own update is controlling here. Achieve expects a CRL by the June 20 PDUFA and is guiding to a Q4 2026 NDA resubmission. Treat this as a manufacturing-reset disclosure event, not an 82% approval setup.
|
|
+
|
VERA / ATACICEPT — CONFIRMATORY PATH PULLED FORWARD
Vera aligned with FDA on an earlier ORIGIN 3 eGFR confirmatory analysis plan. The eGFR analysis is now expected in Q3 2026, with a planned Q4 2026 sBLA if the data are supportive. July 7 remains the first event, but the post-PDUFA path is now more defined.
|
|
X
|
CORT / RELACORILANT — STILL EXCLUDED
The raw file still shows a July 11 PDUFA, but that entry remains stale. FDA already approved relacorilant with nab-paclitaxel for the relevant ovarian cancer indication, so CORT is not included on the live board.
|
| PDUFA | Window | Ticker | Event | PoA |
| Thu Jun 18 | Thu Jun 18 | SPRO | tebipenem HBr / cUTI, incl. pyelo | 92.5% |
| Sat Jun 20 | Thu 18 / Mon 22 | ACHV | cytisinicline / smoking cessation | CRL exp. |
| Mon Jun 29 | Mon Jun 29 | ARQT | ZORYVE® cream / psoriasis, ages 2–5 | 95%+ |
| Mon Jun 29 | Mon Jun 29 | LNTH | LNTH-2501 / SSTR+ NET imaging | 92.5% |
| Tue Jun 30 | Tue Jun 30 | IONS | TRYNGOLZA® / severe HTG | 92.5% |
| Tue Jul 7 | Tue Jul 7 | VERA | atacicept / IgA nephropathy | 78% |
| Fri Jul 17 | Fri Jul 17 | CELC | gedatolisib / HR+ HER2- PIK3CA WT BC | n/s |
| Sun Jul 26 | Fri 24 / Mon 27 | MNKD | FUROSCIX ReadyFlow Autoinjector | 73% |
| Thu Jul 30 | Thu Jul 30 | VTRS | MR-100A-01 / low-dose estrogen weekly patch | 92.5% |
| SPRO $SPRO · tebipenem HBr · cUTI, incl. pyelo | PDUFA: Thu Jun 18 PoA 92.5% |
This is the next clean approval clock. The asset is partnered with GSK, the NDA was resubmitted after the PIVOT-PO Phase 3 success, and the clinical setup is unusually clean for the current board: oral carbapenem, complicated UTI including pyelonephritis, noninferiority to IV imipenem-cilastatin, and a clear unmet-need story around outpatient / step-down treatment.
The question is not whether the product has a plausible clinical role. The question is whether FDA is ready to clear the first oral carbapenem in this setting without narrowing the label or creating a stewardship-heavy launch constraint.
| ACHV $ACHV · cytisinicline · smoking cessation | PDUFA: Sat Jun 20 CRL expected |
This remains a live FDA event, but not an approval watch. Achieve has already told investors it expects a CRL by the June 20 action date. The issue is manufacturing / inspection-related, not a known clinical efficacy failure.
The company has completed technology transfer to Adare Pharma Solutions and is guiding to a Q4 2026 NDA resubmission, with a potential first-half 2027 launch. This makes ACHV a reset-timing story, not a standard approval binary.
| ARQT $ARQT · ZORYVE® cream · psoriasis ages 2–5 | PDUFA: Mon Jun 29 PoA 95%+ |
A pediatric label-expansion setup around an already approved and commercialized dermatology franchise. ZORYVE cream is already approved for plaque psoriasis down to age 6; the current sNDA seeks to extend the label to ages 2–5.
| LNTH $LNTH · Ga 68 edotreotide · SSTR+ NET imaging | PDUFA: Mon Jun 29 PoA 92.5% |
Still a high-confidence diagnostic-imaging setup, but the review history matters. FDA extended the review by three months to June 29 to review manufacturing-related information. The company said the extension was not related to efficacy or safety data.
| IONS $IONS · TRYNGOLZA® · severe HTG | PDUFA: Tue Jun 30 PoA 92.5% |
A high-confidence late-June label-expansion setup. TRYNGOLZA is already approved for familial chylomicronemia syndrome, and the current Priority Review is for severe hypertriglyceridemia. The key watch item is label language around pancreatitis-risk reduction and eligible triglyceride thresholds.
| VERA $VERA · atacicept · IgA nephropathy | PDUFA: Tue Jul 7 PoA 78% |
This is now a more defined accelerated-approval sequence. The July 7 PDUFA is still the first event: whether FDA is comfortable approving atacicept on the Phase 3 proteinuria package while ORIGIN 3 continues.
Vera has also aligned with FDA to pull the ORIGIN 3 eGFR confirmatory analysis forward to Q3 2026, with a planned Q4 2026 sBLA if the eGFR data are supportive.
| CELC $CELC · gedatolisib · HR+ HER2- PIK3CA WT BC | PDUFA: Fri Jul 17 n/s |
Inside the July board. FDA granted Priority Review and accepted the NDA for HR+/HER2-/PIK3CA wild-type advanced breast cancer. Recent data noise is worth separating from the filed indication: newer PIK3CA-mutant data may affect sentiment, but should not be treated as the core basis for the July 17 action date.
| MNKD / VTRS outer-board watch | Jul 26 / Jul 30 |
MNKD enters the outer edge of the six-week board with FUROSCIX ReadyFlow. This is more device / delivery execution than new-drug efficacy. VTRS sits just beyond the window with MR-100A-01, a 505(b)(2) low-dose estrogen contraceptive patch application.
The board is no longer quiet.
CAMX joins CING in the CMC-reset bucket. ACHV is still live, but only as a CRL / resubmission-timing event. SPRO is the week’s clean approval clock. VERA now has a more defined post-PDUFA path: accelerated approval first, then Q3 eGFR, then potential Q4 sBLA.
| SPRO | → | ACHV | → | ARQT / LNTH | → | IONS |
| VERA | → | CELC | → | MNKD / VTRS |
That is the queue.
Informational only · Not investment advice · Biotech carries risk of total loss